Physician profile
Stuart Gildenberg
NPI 1194720276
$7,740.73
in general payments reported to CMS, 2019-2025
28 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $672 · 2021: $947 · 2022: $1,236 · 2023: $1,628 · 2024: $1,524 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,094 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,093.67 |
| Education | $187.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,670.73 | 2019-2025 | |
| Janssen Biotech, INC. | $1,054.79 | 2019-2024 | Tremfya, Remicade, Stelara |
| Genzyme Corporation | $903.64 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $780.92 | 2019-2025 | |
| Leo Pharma INC. | $768.45 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $481.60 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $479.98 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $301.07 | 2022-2024 | Vtama |
| Journey Medical Corporation | $194.57 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $186.40 | 2019-2025 | Winlevi |
| Arcutis Biotherapeutics, INC. | $171.76 | 2024-2025 | Zoryve |
| Prugen, INC. Pharmaceuticals | $136.54 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $104.56 | 2020 | |
| Galderma Laboratories, L.P. | $94.11 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.88 | 2023-2024 | Spevigo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $64.95 | 2021 | |
| Encore Dermatology INC. | $35.86 | 2019-2020 | |
| Biofrontera INC. | $34.00 | 2019-2021 | |
| Amgen INC. | $31.55 | 2025 | Otezla |
| Ucb, INC. | $25.78 | 2025 | Bimzelx |
| Incyte Corporation | $24.86 | 2021 | |
| Organon LLC | $20.49 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.19 | 2023 | Arazlo, Jublia |
| Epi Health, LLC | $17.50 | 2022 | |
| Lilly USA, LLC | $16.08 | 2020 | |
| Vyne Pharmaceuticals INC. | $15.65 | 2020 | |
| Mission Pharmacal Company | $15.26 | 2019 | |
| Mayne Pharma Commercial LLC | $9.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Gildenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.